Skip to content

Insulet PODD Price / earnings

Price / earnings at other companies

Eli Lilly logo
Eli LillyLLY
32.5×-34.3×
Medtronic logo
MedtronicMDT
21.7×-1.5×
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
33.3×-1.4×
Abbott logo
AbbottABT
28.4×+11.4×
Viatris logo
ViatrisVTRS
6.5×-6.4×

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Calculated from Insulet’s reported figures.

Based on the most recent quarter.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's price / earnings?
Insulet (PODD) reported price / earnings of 48.8× in Q1 2026.
How has Insulet's price / earnings changed year-over-year?
Insulet's price / earnings increased by 6.4% year-over-year, from 45.9× to 48.8×.
What is the long-term trend for Insulet's price / earnings?
Over 4 years (2021 to 2025), Insulet's price / earnings has grown at a -47.8% compound annual growth rate (CAGR), from 1,092.3× to 80.9×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.